This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The two strategies were omalizumab added to inhaled corticosteroids (ICS) and quick relievers when needed, compared with ICS and quick relievers. Dosing for omalizumab was based on both immunoglobulin E (IgE) level and weight (0.016mg/kg IgE).
Location/setting
USA/primary and secondary care.
Methods

Analytical approach:
This economic evaluation was based on the published Asthma Policy Model, which was a Markov state-transition model simulation of the natural history and treatment of asthma. The time horizon of the analysis was 10 years and the authors stated that the perspective was societal.
Effectiveness data:
The clinical data were derived from a selection of known, relevant studies and the authors' opinions. The details of the published sources, for some inputs, were given. For example, some data on the treatment effects of omalizumab plus ICS compared with ICS alone came from a published randomised controlled trial (RCT) and a systematic review. The efficacy of the ICS therapy was based on authors' opinions and on a published study, and it was pointed out that this assumption deliberately favoured omalizumab. The key clinical outcome was the reduction in exacerbation rate and improvement in the forced expiratory volume in one second (FEV 1 ).
Monetary benefit and utility valuations:
The utility valuations were derived from an author's previous work which elicited patients' preferences using the time trade-off approach and other preference measures. The relationship between the predicted FEV 1 and the preference scores was estimated using ordinary least-squares regression.
Measure of benefit:
Quality-adjusted life-years (QALYs) and symptom-free days (SFDs) were used as the summary benefit measures. QALYs were discounted at an annual rate of 3%.
